摘要
Cancer treatments are rapidly changing.Curative treatment for oesophageal adenocarcinoma currently involves surgery and cytotoxic chemotherapy or chemoradiotherapy.Outcomes for both regimes are generally poor as a result of tumor recurrence.We have reviewed the key signalling pathways associated with oesophageal adenocarcinomas and discussed the recent trials of novel agents that attempt to target these pathways.There are many trials underway with the aim of improving survival in oesophageal cancer.Currently,phase 2 and 3 trials are focused on MAP kinase inhibition,either through inhibition of growth factor receptors or signal transducer proteins.In order to avoid tumor resistance,it appears to be clear that targeted therapy will be needed to combat the multiple signalling pathways that are in operation in oesophageal adenocarcinomas.This may be achievable in the future with the advent of gene signatures and a combinatorial approach.
Cancer treatments are rapidly changing. Curative treat- ment for oesophageal adenocarcinoma currently involves surgery and cytotoxic chemotherapy or chemo- radiotherapy. Outcomes for both regimes are generally poor as a result of tumor recurrence. We have reviewed the key signalling pathways associated with oesophageal adenocarcinomas and discussed the re- cent trials of novel agents that attempt to target these pathways. There are many trials underway with the aim of improving survival in oesophageal cancer. Cur- rently, phase 2 and 3 trials are focused on MAP kinase inhibition, either through inhibition of growth factor re- ceptors or signal transducer proteins. In order to avoid tumor resistance, it appears to be clear that targeted therapy will be needed to combat the multiple signalling pathways that are in operation in oesophageal adenocarcinomas. This may be achievable in the future with the advent of gene signatures and a combinatorial approach.
基金
Supported by UK National Institute of Health Research/Cancer Research Network (UK NIHR/UKCRN) and Research and Development Department of Wrightington Wigan and Leigh NHS Foundation Trust (to Ang YS)
R Keld WrightingtonWigan and Leigh NHS Foundation Trust Cancer Therapy Fund(to Keld RR,in part)
关键词
信号通路
食道癌
腺癌
个性化
医药
癌症治疗
生长因子受体
肿瘤耐药
Oesophageal adenocarcinoma
Signallingpathways
MAP and PI3 Kinase pathways
Wnt signalling
Transforming growth factor-13 pathway
Nuclear factor-KBpathways
Transcription factors
Tyrosine kinase receptors
